KalVista Pharmaceuticals, Inc. Stock Xetra
Stocks
4XC1
US4834971032
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.37 EUR | +0.04% |
|
0.00% | - |
| Market Cap | 1.44B 1.25B 1.15B 1.08B 2.01B 138B 2.06B 13.72B 5.31B 66.35B 5.4B 5.28B 231B | P/E Ratio 2026 * |
-30.8x | P/E Ratio 2027 * | 17.5x |
|---|---|---|---|---|---|
| Enterprise Value | 1.3B 1.12B 1.04B 972M 1.82B 124B 1.85B 12.37B 4.79B 59.83B 4.87B 4.76B 208B | EV / Sales 2026 * |
6.21x | EV / Sales 2027 * | 3.51x |
| Free-Float |
98.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: KalVista Pharmaceuticals, Inc.
| 1 day | +0.04% |
| 1 week | 23.27 |  | 23.39 |
| 1 month | 23.27 | | 23.39 |
| Current year | 23.27 | | 23.39 |
| 1 year | 23.27 | | 23.39 |
| 3 years | 23.27 | | 23.39 |
| 5 years | 23.27 | | 23.39 |
| 10 years | 23.27 | | 23.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ed Feener
CTO | Chief Tech/Sci/R&D Officer | 66 | 2016-10-31 |
Ben Palleiko
CEO | Chief Executive Officer | 61 | 2024-03-05 |
Brian Piekos
DFI | Director of Finance/CFO | 51 | 2024-09-08 |
| Director | Title | Age | Since |
|---|---|---|---|
Ben Palleiko
BRD | Director/Board Member | 61 | 2024-03-05 |
Edward Unkart
BRD | Director/Board Member | 76 | 2014-11-30 |
Brian Pereira
CHM | Chairman | 67 | 2022-10-12 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.04% | 0.00% | - | - | 1.44B | |
| +1.65% | +6.42% | +53.16% | +109.62% | 54.82B | |
| +0.03% | -1.80% | +49.57% | +43.94% | 43.27B | |
| +2.92% | -0.94% | -15.84% | -19.16% | 21.79B | |
| +5.99% | -6.98% | -0.39% | +400.51% | 19.92B | |
| +0.81% | -8.38% | +12.77% | -33.24% | 15.67B | |
| +0.53% | +2.08% | +8.89% | -40.13% | 15.26B | |
| +1.93% | +2.13% | +29.40% | +180.83% | 13.22B | |
| -5.27% | +3.89% | +90.88% | +208.02% | 11.58B | |
| -1.74% | -1.05% | +12.88% | - | 11.94B | |
| Average | +0.69% | -0.58% | +26.81% | +106.30% | 23.05B | |
| Weighted average by Cap. | +1.15% | +1.16% | +31.99% | +97.87% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 209M 181M 167M 156M 292M 19.98B 298M 1.99B 771M 9.63B 783M 767M 33.49B | 348M 302M 279M 261M 488M 33.36B 498M 3.32B 1.29B 16.08B 1.31B 1.28B 55.91B |
| Net income | -68.56M -59.49M -54.84M -51.38M -96.01M -6.56B -98.01M -654M -253M -3.16B -257M -252M -11B | 44.07M 38.25M 35.26M 33.03M 61.72M 4.22B 63.01M 421M 163M 2.03B 165M 162M 7.07B |
| Net Debt | -141M -123M -113M -106M -198M -13.53B -202M -1.35B -522M -6.52B -530M -519M -22.68B | -216M -188M -173M -162M -303M -20.71B -309M -2.06B -799M -9.98B -812M -794M -34.71B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-10 | 23.37 € | +0.04% | 0 |
| 26-06-09 | 23.36 € | -0.13% | 0 |
| 26-06-08 | 23.39 € | +0.13% | 0 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- KALV Stock
- 4XC1 Stock
Select your edition
All financial news and data tailored to specific country editions
